Cargando…
Authors’ Reply to Lechat et al.: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768902/ https://www.ncbi.nlm.nih.gov/pubmed/31452151 http://dx.doi.org/10.1007/s40262-019-00815-8 |
| _version_ | 1783455144648638464 |
|---|---|
| author | Concordet, Didier Gandia, Peggy Montastruc, Jean-Louis Bousquet-Mélou, Alain Lees, Peter Ferran, Aude A. Toutain, Pierre-Louis |
| author_facet | Concordet, Didier Gandia, Peggy Montastruc, Jean-Louis Bousquet-Mélou, Alain Lees, Peter Ferran, Aude A. Toutain, Pierre-Louis |
| author_sort | Concordet, Didier |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6768902 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-67689022019-10-16 Authors’ Reply to Lechat et al.: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?” Concordet, Didier Gandia, Peggy Montastruc, Jean-Louis Bousquet-Mélou, Alain Lees, Peter Ferran, Aude A. Toutain, Pierre-Louis Clin Pharmacokinet Letter to the Editor Springer International Publishing 2019-08-27 2019 /pmc/articles/PMC6768902/ /pubmed/31452151 http://dx.doi.org/10.1007/s40262-019-00815-8 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| spellingShingle | Letter to the Editor Concordet, Didier Gandia, Peggy Montastruc, Jean-Louis Bousquet-Mélou, Alain Lees, Peter Ferran, Aude A. Toutain, Pierre-Louis Authors’ Reply to Lechat et al.: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?” |
| title | Authors’ Reply to Lechat et al.: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?” |
| title_full | Authors’ Reply to Lechat et al.: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?” |
| title_fullStr | Authors’ Reply to Lechat et al.: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?” |
| title_full_unstemmed | Authors’ Reply to Lechat et al.: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?” |
| title_short | Authors’ Reply to Lechat et al.: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?” |
| title_sort | authors’ reply to lechat et al.: “levothyrox(®) new and old formulations: are they switchable for millions of patients?” |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768902/ https://www.ncbi.nlm.nih.gov/pubmed/31452151 http://dx.doi.org/10.1007/s40262-019-00815-8 |
| work_keys_str_mv | AT concordetdidier authorsreplytolechatetallevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients AT gandiapeggy authorsreplytolechatetallevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients AT montastrucjeanlouis authorsreplytolechatetallevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients AT bousquetmeloualain authorsreplytolechatetallevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients AT leespeter authorsreplytolechatetallevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients AT ferranaudea authorsreplytolechatetallevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients AT toutainpierrelouis authorsreplytolechatetallevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients |